Needham & Company LLC set a $60.00 price target on Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the stock.
PCRX has been the topic of a number of other reports. Barclays upped their target price on shares of Pacira Pharmaceuticals from $40.00 to $50.00 and gave the company a buy rating in a report on Monday, August 6th. BMO Capital Markets upped their target price on shares of Pacira Pharmaceuticals to $40.00 and gave the company a neutral rating in a report on Thursday, August 2nd. They noted that the move was a valuation call. ValuEngine raised shares of Pacira Pharmaceuticals from a hold rating to a buy rating in a report on Saturday, July 28th. Wedbush set a $85.00 target price on shares of Pacira Pharmaceuticals and gave the company an outperform rating in a report on Monday, August 6th. Finally, Mizuho reiterated a hold rating and issued a $43.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $51.56.
Shares of PCRX stock traded down $1.84 on Thursday, reaching $50.32. The stock had a trading volume of 1,024,467 shares, compared to its average volume of 816,625. The company has a debt-to-equity ratio of 0.98, a quick ratio of 7.79 and a current ratio of 8.58. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -86.76 and a beta of 1.87. Pacira Pharmaceuticals has a 12 month low of $26.95 and a 12 month high of $55.00.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Thursday, November 1st. The company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.40. The company had revenue of $83.45 million for the quarter, compared to analysts’ expectations of $79.87 million. Pacira Pharmaceuticals had a negative net margin of 3.64% and a negative return on equity of 0.39%. Pacira Pharmaceuticals’s quarterly revenue was up 23.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.11 EPS. Sell-side analysts predict that Pacira Pharmaceuticals will post -0.21 EPS for the current fiscal year.
In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 1,000 shares of the stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $50.70, for a total transaction of $50,700.00. Following the transaction, the vice president now owns 11,474 shares in the company, valued at approximately $581,731.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Kristen Marie Williams sold 4,773 shares of the stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $47.04, for a total transaction of $224,521.92. Following the transaction, the chief accounting officer now owns 22,374 shares in the company, valued at approximately $1,052,472.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,502 shares of company stock worth $1,913,864. 5.90% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. Bouchey Financial Group Ltd acquired a new position in shares of Pacira Pharmaceuticals during the 3rd quarter worth approximately $221,000. US Bancorp DE grew its position in shares of Pacira Pharmaceuticals by 40.7% during the 2nd quarter. US Bancorp DE now owns 6,038 shares of the company’s stock worth $194,000 after purchasing an additional 1,746 shares in the last quarter. Seven Eight Capital LP acquired a new position in shares of Pacira Pharmaceuticals during the 3rd quarter worth approximately $308,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Pacira Pharmaceuticals during the 3rd quarter worth approximately $326,000. Finally, Cubist Systematic Strategies LLC grew its position in shares of Pacira Pharmaceuticals by 1,925.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock worth $214,000 after purchasing an additional 6,336 shares in the last quarter.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Further Reading: Determine Your Level of Risk Tolerance
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.